Our laboratory uses modern genomic and proteomic tools to discover the underlying biological mechanisms that lead to drug resistance in childhood acute leukemia. We have identified gene signatures that correlate with prognosis allowing us to tailor therapy to the predicted risk of relapse. Moreover by comparing the transcriptome of cancer cells at initial diagnosis to those at relapse we have discovered pathways that mediate drug resistance. We are now validating the functional relevance of these pathways and seek to develop targeted therapy.